Field efficacy of an inactivated bivalent influenza vaccine in a multi-site Swine production system During an outbreak of systemic porcine circovirus associated disease

Canadian Journal of Veterinary Research

Volumn 74, Issue 2, 2010, Pages 108-117

  Poljak, Zvonimir ^a   Dewey, Catherine E ^a   Martin, S Wayne ^a   Christensen, Jette ^b   Friendship, Robert M ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b CANADIAN FOOD INSPECTION AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

ARTICLE; CANADA; CIRCOVIRIDAE; CONTROLLED STUDY; DRUG EFFICACY; EPIDEMIC; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PIG FARMING; PORCINE CIRCOVIRUS ASSOCIATED DISEASE; SWINE; SWINE DISEASE; SWINE INFLUENZA VIRUS; WEIGHT GAIN;

ANIMALS; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; INFLUENZA VACCINES; SWINE; SWINE DISEASES; VACCINES, INACTIVATED;

PORCINE CIRCOVIRUS; SUIDAE;

EID: 77951472753     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ito T, Couceiro JN, Kelm S, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol 1998;72:7367-7373.
2. Loeffen WL, Kamp EM, Stockhofe-Zurwieden N, et al. Survey of infectious agents involved in acute respiratory disease in finishing pigs. Vet Rec 1999;145:123-129.
3. Easterday BC, Van Reeth K. Swine influenza. In: Straw B, ed. Diseases of Swine. 8th ed. Ames, Iowa: Iowa State Univ Pr 1999: 277-290.
4. Elbers AR, Tielen MJ, Cromwijk WA, Hunneman WA. Variation in seropositivity for some respiratory disease agents in finishing pigs: Epidemiological studies on some health parameters and farm and management conditions in the herds. Vet Q 1992;14:8-13.
5. Thacker EL. Immunology of the porcine respiratory disease complex. Veterinary Clinics of North America: Food Animal Practice 2001;17:551-563.
6. Heinen PP, van Nieuwstadt AP, de Boer-Luijtze EA, Bianchi AT. Analysis of the quality of protection induced by a porcine influenza A vaccine to challenge with an H3N2 virus. Vet Immunol Immunopathol 2001;82:39-56.
7. Van Reeth K, Labarque G, De Clercq S, Pensaert M. Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection. Vaccine 2001;19:4479-4486.
8. Kitikoon P, Vincent A, Jones K, et al. Influence of PRRS virus infection on swine influenza vaccine efficacy. In: Proceedings of the 35th Annual Meeting of American Association of Swine Veterinarians. Des Moines, Iowa, USA. March 6-9, 2004:427-430.
9. Canadian Council on Animal Care. Guide to the care and use of experimental animals. 2nd ed. Ottawa, Ontario, Canada: Canadian Council on Animal Care, 1993:212.
10. Canadian Council on Animal Care. Guidelines on: Choosing an appropriate endpoint in experiments using animals for research, teaching and testing. Ottawa, Ontario, Canada: Canadian Council on Animal Care, 1998:30.
11. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, New Jersey: John Wiley &Sons, 2004:506.
12. ® 9.1 User's Guide. Carry, NC.: SAS Institute Inc., 2004:5136.
13. Dohoo I, Martin W, Stryhn H. Veterinary Epidemiologic Research. Charlottetown, Prince Edward Island, Canada: AVC Inc., 2003:706.
14. Segales J, Domingo M. Postweaning multisystemic wasting syndrome (PMWS) in pigs. A review. Vet Q 2002;24:109-124.
15. Poljak Z. Prevalence, clustering, and risk factors for pathogens of public health significance in the Ontario swine industry. PhD thesis. 1-26-2006. Guelph, Ontario, Canada, Department of Population Medicine.
16. Van Reeth K. The protective immune response to swine influenza virus: The European experience. In: Proceedings of the 36th Annual Meeting of American Association of Swine Veterinarians. Toronto, Ontario, Canada. March 5-8, 2005:493-497.
17. Loeffen WL, Nodelijk G, Heinen PP, van Leengoed LA, Hunneman WA, Verheijden JH. Estimating the incidence of influenza-virus infections in Dutch weaned piglets using blood samples from a cross-sectional study. Vet Microbiol 2003;91:295-308.
18. Yoon KJ, Janke BH, Swalla RW, Erickson G. Comparison of a commercial H1N1 enzyme-linked immunosorbent assay and hemagglutination inhibition test in detecting serum antibody against swine influenza viruses. J Vet Diagn Invest 2004;16:197-201.
19. Loeffen WL, Heinen PP, Bianchi AT, Hunneman WA, Verheijden JH. Effect of maternally derived antibodies on the clinical signs and immune response in pigs after primary and secondary infection with an influenza H1N1 virus. Vet Immunol Immunopathol 2003;92:23-35.
20. Kitikoon P, Nilubol D, Erickson BJ, Janke BH, Hoover TC, Sornsen SA, Thacker EL. The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination. Vet Immunol Immunopathol 2006;112:117-128.
21. Fleck R, Behrens A. Evaluation of a maternal antibody decay curve for H1N1 swine influenza virus using the hemagglutination inhibition and the IDEXX ELISA test. In: Proceedings of the 33rd Annual Meeting of American Association of Swine Veterinarians. Kansas City, Missouri, USA. March 2-5, 2002:109-110.
22. Vincent AL, Lager KM, Janke BH, Gramer MR, Richt JA. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet Microbiol 2008;126:310-323.
23. Lee JH, Gramer MR, Joo HS. Efficacy of swine influenza A virus vaccines against an H3N2 virus variant. Can J Vet Res 2007;71:207-212.
24. Olsen CW, Karasin AI, Carman S, et al. Triple reassortant H3N2 influenza A viruses, Canada, 2005. Emerg Infect Dis 2006;12:1132-1135.
25. Poljak Z, Friendship R, Carman S, McNab W, Dewey C. Investigation of exposure to influenza viruses in Ontario (Canada) finisher herds in 2004 and 2005. Prev Vet Med 2008;83:24-40.
26. Krakowka S, Ellis JA, McNeilly F, Ringler S, Rings DM, Allan G. Activation of the immune system is the pivotal event in the production of wasting disease in pigs infected with porcine circovirus-2 (PCV-2). Vet Pathol 2001;38:31-42.
27. Opriessnig T, Meng XJ, Halbur PG. Porcine circovirus type 2 associated disease: Update on current terminology, clinical manifestations, pathogenesis, diagnosis, and intervention strategies. J Vet Diagn Invest 2007;19:591-615.
28. Opriessnig T, Halbur PG, Yu S, Thacker EL, Fenaux M, Meng XJ. Effects of the timing of the administration of Mycoplasma hyopneumoniae bacterin on the development of lesions associated with porcine circovirus type 2. Vet Rec 2006;158:149-154.
29. Hoogland MJ, Opriessnig T, Halbur PG. Effects of adjuvants on porcine circovirus type 2-associated lessions. J Swine Health Prod 2006;14:133-139.
30. Ladekjaer-Mikkelsen AS, Nielsen J, Stadejek T, et al. Reproduction of postweaning multisystemic wasting syndrome (PMWS) in immunostimulated and non-immunostimulated 3-week-old piglets experimentally infected with porcine circovirus type 2 (PCV2). Vet Microbiol 2002;89:97-114.
31. Resendes A, Segalés J, Balasch M, Calsamiglia M, et al. Lack of an effect of a commercial vaccine adjuvant on the development of postweaning multisystemic wasting syndrome (PMWS) in porcine circovirus type 2 (PCV2) experimentally infected conventional pigs. Vet Res 2004;35:83-90.
32. Opriessnig T, McKeown NE, Harmon KL, Meng XJ, Halbour PG. Porcine circovirus type 2 infection decreases the efficacy of a modified live porcine reproductive and respiratory syndrome virus vaccine. Clin Vaccine Immunol. 2006;13:923-929.